In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

An outbreak of a novel coronavirus (COVID‐19 or 2019‐CoV) infection has posed significant
threats to international health and the economy. In the absence of treatment for this virus …

Aims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan,
China (COVID-19). Until today> 2700 deaths from the 80,000 confirmed cases reported …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

Confronting the challenge of the outbreak of COVID‐19 should sharpen our focus on global
drug access as a key issue in antiviral therapy testing. The testing and adoption of effective …

Type I interferons (IFNs)(IFN-α, IFN-β) and type III IFNs (IFN-λ) share many properties,
including induction by viral infection, activation of shared signaling pathways, and …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage,
which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

Background The revolution in hepatitis C virus (HCV) treatment through the development of
direct-acting antivirals (DAAs) has generated international interest in the global elimination …